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ABSTRACT 
 As of 2019, marijuana legalization and decriminalization is sweeping the globe. 
Patients are increasingly using cannabis-derived compounds including Δ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD) for treatment of diseases as diverse 
as epilepsy, Parkinson’s disease, and cancer. Furthermore, mothers are claiming that 
CBD oil decreases uncomfortable pregnancy side effects. While the adverse effects of 
chronic cannabinoid use and of cannabinoids on pregnancy have been previously 
investigated, the exact function of the endocannabinoid system, and its primary receptors, 
cannabinoid receptors 1 and 2, involved in producing these outcomes is still unclear. In 
this study, two strains of zebrafish embryos, namely fli and cnr2-/- were exposed to 
varying concentrations of CBD and THC for 96 hpf and their developmental and 
behavioral outcomes were observed to further determine the role that CB2 plays in 
embryonic development and organogenesis. Fli larvae had a higher percent incidence of 
pericardial edema and yolk sac edema when exposed to 0.6 mg/L CBD, whereas CBD 
treated cnr2-/- were not significantly different than untreated. Fli larvae also showed an 
increased percent incidence of yolk sac edema at 2.5 mg/L THC and a percent incidence 
not different from control, or 2.5 mg/L at 1.25 mg/L, whereas cnr2-/- only suffered from 
yolk sac edema at 2.5 mg/L THC. Behavioral patterns were treatment-dependent, as both 
THC and CBD showed increased activity at 0.65 mg/L and 0.075 mg/L, respectively. 
These studies indicate that cannabinoid developmental toxicity depends both on the 
particular cannabinoid and its interactions with the CB2 receptor. Additional studies are 
needed to investigate the THC and CBD toxicities in the cnr1-/- to further understand the 
mechanisms of cannabinoid toxicity.  
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I. Introduction 
1.0 Cannabis 
Society views cannabis in several ways due to its medicinal and recreational usage. 
Some see cannabis as a gateway drug, preceding the use of other illicit and licit 
substances and the development of substance abuse and addiction (“Is marijuana a 
gateway drug? National Institute on Drug Abuse (NIDA),” n.d.). Others see this drug for 
its therapeutic use in treating diseases, such as cancer, glaucoma, nerve pain, seizure 
disorders, Crohn’s Disease, and muscle spasms due to multiple sclerosis (Elikkottil et al., 
2009). Many expecting mothers view cannabis as a method of avoiding hyperemesis 
gravidarum (morning sickness), and other pregnancy discomforts (Roberson et al., n.d.). 
Regardless of how this plant is stigmatized, cannabis is a blanket term for three species of 
hemp plants (Cannabis sativa, Cannabis indica, Cannabis ruderalis) (“Is marijuana a 
gateway drug? National Institute on Drug Abuse (NIDA),” n.d.). The term marijuana 
describes the dried components from the hemp plant, such as leaves, seeds, and stems, 
that are often smoked or eaten (Campbell et al., 2017). 
Marijuana is classified into two categories: recreational and medical (What is 
marijuana?, 2018). Recreational marijuana use has been legalized in nine states- Oregon, 
Washington, Colorado, Alaska, Nevada, Maine, Massachusetts, California, Vermont- and 
the District of Columbia as of March 2019 (Martin, 2018). Pushes for recreational 
marijuana usage legalization has increased, with 60% of the American population 
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supporting the idea, as most Americans believe that marijuana is not harmful and has no 
adverse effects (Martin, 2018). Medical marijuana is the use of physician-prescribed 
marijuana. Medical marijuana itself has not been approved by the U.S. Food and Drug 
Administration (FDA), but it is often confused for FDA-approved drugs that contain 
cannabinoids. Both recreational and medical marijuana can have the same harmful effects 
during pregnancy, such as small birth size, stillbirth, and birth deformations (Gunn et al., 
2016). Many medical marijuana patients in California and in other states with legalized 
medical marijuana often feel stigmatized by others (Satterlund et al., 2015).  
Regardless of stigma and side effects of cannabis, the cannabis industry is rapidly 
growing. Canada was the second country to fully legalize cannabis in October of 2018. 
Since then, there has been a mass movement in Canada of cannabis producers working 
with scientists on gene mapping, metabolic engineering, optimal drying techniques, and 
growing practices in an effort to corner the global cannabis market (Dolgin, 2018). 
Globally, the cannabis market is forecast to surpass US$57 billion within the decade 
(Dolgin, 2018). Federal and provincial Canadian governments, government backed 
organizations such as Genome Canada, and private investors are giving millions of 
dollars to cannabis research to aid in this effort. In 2017 alone, Canadian cannabis 
companies brought in US$1.5 billion, greater than half of worldwide funding raised by 
legal cannabis firms, and the Canadian cannabis industry was projected to and did triple 
that number in 2018 (Dolgin, 2018). As countries across the world have seen the ongoing 
success of the Canadian cannabis industry, there has been an international trend toward 
less restrictive laws around cannabis, allowing for further investment in genetic research. 
This plant genetic research has allowed for the isolation and study of the two medically 
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useful cannabinoids from the cannabis plant: Δ9-tetrahydrocannabinol and cannabidiol 
(Dolgin, 2018). 
1.0.1. Δ9-Tetrahydrocannabinol 
 Of cannabis drug chemotypes, Δ9-tetrahydrocannabinol is the most common 
phytocannabinoid. In its acid form, THC is produced in the cannabis plant via an allele 
codominant with CBD. The primary difference between THC and CBD is that THC 
produces psychoactive effects once burned (Russo, 2016). THC causes these effects 
through weak partial agonist activity at cannabinoid receptors 1 and 2 (CB1, CB2), which 
results in the common effects of ingesting cannabis, such as increased appetite, reduced 
pain, and changes in emotional and cognitive processes (Russo, 2016). THC is also a 
neuroprotective antioxidant, bronchodilator, antipruritic agent in cholestatic jaundice, and 
is a better anti-inflammatory than both aspirin and hydrocortisone (Russo, 2016). 
Dronabinol (marketed as Marinol) is a medication utilizing synthetic THC that is 
prescribed to treat anorexia in AIDS patients and nausea and vomiting associated with 
cancer chemotherapy.  
1.0.2 Cannabidiol  
Cannabidiol (CBD) is the main non-intoxicating phytocannabinoid produced by 
the cannabis plant. CBD is currently being produced in marijuana legalized states without 
any regulation, resulting in products that vary widely in purity (Thompson and Kearney, 
2016). CBD has a low affinity for cannabinoid receptors but has CB1 and CB2 
independent mechanisms. These mechanisms may account for CBD’s ability to act as a 
negative allosteric modulator at CB1 receptor sites (Laprairie et al., 2015). Dispensaries 
sell CBD products in states with legalized marijuana and no CBD-specific laws. Only 
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physicians can provide CBD products in states that have not legalized marijuana due to 
restrictions on CBD dispensing. CBD-enriched extracts have been tested and 
administered primarily in relation to medicinal use to treat anxiety, inflammation, 
sleeplessness, and seizure activity.  
In animal models, CBD has proven to lack adverse psychoactive effects, abuse 
liability and have a better defined anticonvulsant profile than THC (Rosenberg et al., 
2015). Due to these factors, physicians have increased the use of CBD-enriched extracts, 
such as the FDA approved CBD medication Epidiolex, to treat seizure disorders 
especially in children (Reddy and Golub, 2016; Thompson and Kearney, 2016). Data 
regarding the use of CBD-enriched extracts in treatment show improvement in seizure 
control, sleep, and behavior; this data has been difficult to interpret due to lack of control 
in these observations (Consroe et al., 1982; Jones et al., 2010; Klein et al., 2017). 
However, three therapy trials for a purified CBD product utilizing high-quality placebo 
control were performed on patients with epilepsy syndromes (Devinsky et al., 2014). 
These studies demonstrated CBD superior to placebo in improving seizure control in 
patients with both Dravet syndrome and Lennox-Gastaut syndrome epilepsy. While these 
results are the first indication that CBD is useful in treating seizures, the exact biological 
mechanism of how CBD induces seizure control are unknown (Perucca, 2018).  
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Table 1. Summary of THC and CBD chemical properties. All THC information was acquired 
from pubchem.ncbi.nlm.nih.gov. All CBD information was acquired from drugbank.ca. 
 THC CBD 
Structure    
Molecular formula C21H30O2 C21H30O2 
Molecular weight 314.469 g·mol−1 314.469 g·mol−1 
pKa 10.6 9.13 
log kow 6.97 6.1 
Water solubility at 23 C 2.8 mg/L 1.26 mg/L 
 
1.1 Endocannabinoid system 
The endocannabinoid system is composed of cannabinoid receptors expressed 
throughout the mammalian central and peripheral nervous system and endocannabinoids. 
Endocannabinoids like anandamide are endogenous lipid-based retrograde 
neurotransmitters that act as ligands for cannabinoid receptors (Di Marzo et al., 2007). 
Endogenous cannabinoids are eicosanoids, compounds derived from polyunsaturated 
fatty acids that play a vital role in cell signaling (“Eicosanoid" Definition of Eicosanoid 
by Merriam-Webster,” n.d.). Phytocannabinoids, such as THC and CBD, share the 
lipophilic nature of eicosanoids, giving them the capability to nonspecifically alter 
membrane permeability and interact with specific receptor binding sites, specifically CB1 
and CB2 (Di Marzo et al., 2007). Other receptors in the endocannabinoid system include 
orphan G-protein coupled receptors, such as GPR18, GPR55, and GPR119, and TPRV 
proteins (Irving et al., 2017). The endocannabinoid system as a whole is not fully 
understood at this point and is an active area of ongoing research.  
 In terms of function, the endocannabinoid system is involved in several 
physiological processes, such as inflammation, learning, memory, cardiovascular 
function, pain, emotional regulation and stress, and the sleep/wake cycle (“KEGG 
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DRUG: Dronabinol,” n.d.). Through the CB1/CB2 independent or cooperative 
interaction— based on a neuronal population’s role in regulating physiological 
function— these receptors are involved in mood and cognition alterations and other 
cannabinoid induced central nervous system effects (NCBI, 2018; Onaivi et al., 2015). 
The role of other orphan GPCRs is still being studied. 
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Phytocannabinoids  
Δ9-Tetrahydrocannabinol 
 
Cannabivarian 
 
Cannabidiol-
dimethylheptyl 
 
Cannabidiol  
Ajulemic acid 
 
Endogenous cannabinoids  
Anadamide 
 
2-Arachidonyl glycerol 
 
2-Arachidonyl glycerol 
ether  
O-Arachidonyl 
ethanolamine 
 
N- Arachidonyl dopamine 
 
Figure 1: List of cannabinoids: Phytocannabinoids, Synthetic cannabinoids, and 
Eicosanoids. All figures were acquired from pubchem.ncbi.nlm.nih.gov and drugbank.ca. 
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1.1.1 CB1 
Cannabinoid receptor type 1 is located throughout the central and peripheral nervous 
system (Polston and Wallace, 2017). According to NCBI, the highest concentrations of 
CB1 are in the brain, then fat cells, then the placenta (Jiang et al., 2007). CB1 is a member 
of the guanine protein coupled receptor family and are coupled to pertussis toxin 
sensitive G-protein. This coupling suppresses adenylate cyclase and cAMP formation 
upon activation of the receptor, resulting in lesser signal amplification and reaction to 
signals (Howlett et al., 2010). However, CB1 also activates G-protein coupled receptors 
via activation of specific isoforms of adenylate cyclase (Elikkottil et al., 2009). CB1 
stimulates cAMP by coupling to G-proteins when the dopamine receptor 2 is activated in 
striatal neurons (Maneuf and Brotchie, 1997). This results in the activation of dopamine 
receptors in the brain. Also, CB1 receptors are found in both the central and peripheral 
nervous system, and are most abundant in the hippocampus and amygdala, which are the 
areas of the brain responsible for short-term memory storage and emotional regulation 
(Kaur et al., 2016). Considering this relationship between CB1 and dopamine receptors 
and CB1 location, CB1 has been linked to diseases such as Parkinson’s disease, 
schizophrenia, depression, drug addiction, eating disorders, and autism spectrum 
disorders (Onaivi et al., 2015a; Politis et al., 2017).  
1.1.2 CB2 
Cannabinoid receptor 2 is also located throughout the peripheral and central nervous 
systems, however it is primarily located on lymphoid tissue and in inflammatory cells 
(monocytes, mast cells, B/T cells), as it is involved in immune function regulation (Kaur 
et al., 2016). CB2 is found in peripheral tissues, such as the GI tract, cardiovascular 
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system, liver, bone, adipose tissue, and reproductive system (Polston and Wallace, 2017; 
Zou and Kumar, 2018). CB2 is also a member of the guanine protein coupled receptor 
family and is coupled to pertussis toxin sensitive G-protein. This coupling suppresses 
adenylate cyclase and cAMP formation upon activation of the receptor, resulting in lesser 
signal amplification and reaction to signals (Howlett et al., 2010). Unlike CB1, CB2 only 
has inhibitory effects as it blocks production of adenylate cyclase and cAMP. As 
inflammatory cells are generated in bone marrow and CB2 has been found in bone, both 
deletion and overexpression of CB2 has been linked to bone deformity and development 
(Lerner et al., 2008). However, the exact function and mechanism of CB2 is not yet clear.  
1.2 Past cannabinoid receptor studies yield inconclusive data 
Literature has shown that the deletion of CB1 results in different intra-species 
phenotypes (Lerner et al., 2008). For example, two opposing studies regarding bone 
formation were performed on different strains of mice. In one strain, deletion of CB1 
resulted in decreased rate of bone formation, increased osteoclast count, and a low bone 
mass phenotype (Tamm et al., 2013). In another strain, deletion of CB1 resulted in a 
higher bone mass phenotype and genetic protection from ovariectomy-induced bone loss 
(Bab and Zimmer, 2008). Due to conflicting studies such as these, the exact function of 
CB1 has not been elucidated. 
There is even less known about the exact function of CB2 than that of CB1. While not 
primarily located in the central nervous system, CB2 has neuronal and functional 
expression in the brain, and therefore, a role in neuropsychiatric disorders (Onaivi et al., 
2015b). CB2 has also been linked to bone formation; the deletion of the cannabinoid 
receptor 2 gene in mice caused increased bone turnover and subsequent low bone mass 
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phenotype (Ofek et al., 2006). CB2 mRNA was also detected in osteoblasts, osteoclasts, 
and osteocytes (Lerner et al., 2008). 
1.3 Adverse outcomes of cannabinoid exposure  
With cannabis on the forefront of medical advancement, it is important to know how 
this drug affects people, especially children and the elderly. As cannabis is a promiscuous 
drug and participates in nonspecific ligand binding, cannabis can affect individuals 
differently based on genetics, environment, potency of the drug, and purity of compound 
(Di Marzo et al., 2007; Martin, 2018). For example, one study reported no association 
between cannabis exposure and fetal congenital malformations after analyzing data from 
153 cannabis non-users and 4,892 cannabis users (Warshak et al., 2015). On the other 
hand, another study found an association between higher rates of cannabis use and 19 of 
54 selected malformations (Forrester and Merz, 2006). While an association was found, 
the study did not consider confounding variables, other substances, or multiple 
comparisons, as the study only performed bivariate comparisons. Two case studies also 
found a relationship between cannabis use and fetal malformations, but, due to the nature 
of a case study, these results cannot be applied to the greater population (Gunn et al., 
2016).  
THC causes short and long term effects, which can vary depending on the person and 
the potency (Martin, 2018). Short term effects of THC exposure in humans include 
impaired ability to think and solve problems, coordination, judgment, memory, and mood 
(Crean et al., 2011). The effects of chronic use include memory loss, trouble learning and 
thinking, changes in brain structure, and trouble in the work place (Crean et al., 2011). In 
terms of bodily health, THC ingestion by vaporization or dabbing, two means of 
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smoking, can lead to issues in lung function, such as chronic cough and trouble breathing 
(Russell et al., 2018). Over-exposure to THC can cause adverse effects including intense 
nausea and vomiting, increased heart rate, which may increase one’s risk of heart attack, 
and mental health disorders, such as depression, anxiety, schizophrenia, psychosis, and 
neurodevelopment deficiencies in adolescents (Borgelt et al., 2013; Meier et al., 2012). 
There is scant literature regarding the short and long term effects of CBD exposure. 
The developmental effects of transplacental and post-natal exposure to THC has not 
been well researched. Early research suggests that mothers who smoked marijuana during 
pregnancy gave birth to children with emotional, attention, memory, and impulsive 
behavioral issues (Huizink and Mulder, 2006). THC can also diffuse into breast milk, but 
the effects on the brains of babies drinking contaminated breast milk are not clear 
(National Academies of Sciences et al., 2017). Studies also show that marijuana use 
during pregnancy can produce fetal adverse outcomes, such as low birth weights and 
physical deformities (Shiono et al., 1995). However, the relationship between cannabis 
use during pregnancy and other outcomes, such as still birth, developmental deformities, 
etc., are still unclear (Gunn et al., 2016). Regarding behavioral effects of early age THC 
exposure, mice exposed to cannabinoids at adolescence suffered from decreased 
reactivity of the dopamine reward centers found in the brain; these findings suggest that 
THC has adverse impacts on early age behavior (Fransquet et al., 2017). 
The potential developmental effects of early age CBD exposure have not been 
well studied either. In terms of physiology, organogenesis, development, and behavior, 
there is little literature regarding the effects of CBD exposure. 
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1.4 Zebrafish as a model organism 
Zebrafish is the model organism for this study for several reasons. First of all, 
zebrafish are very easy to keep and breed. Zebrafish are relatively small, as the adult 
zebrafish usually does not grow more than 5-6 cm in body length. Zebrafish also 
naturally live in large groups. Therefore, large quantities of zebrafish can be kept in a 
fairly restricted space (Glass and Dahm, 2004). Secondly, zebrafish produce large 
numbers of translucent embryos when spawned. The translucent nature of the embryos, 
and even the larvae during their first few days of development, allow for scientists to 
observe embryonic development in real time. These embryos also develop very rapidly. 
At 24 hours post fertilization (hpf), all major zebrafish organs are recognizable but not 
yet functioning. At 24-48 hpf, cell types differentiate, causing organs to gradually begin 
working. At 49-72 hpf larvae hatch and begin swimming and hunting for food by 120 
hpf. At 3-4 months post fertilization, zebrafish reach sexual maturity (Glass and Dahm, 
2004). Large numbers of offspring production, embryo transparency, and rapid 
embryonic development make the zebrafish the ideal model for observing how genes 
regulate embryonic development and behavior (Glass and Dahm, 2004) 
The zebrafish is also a particularly good model for human pharmaceutical testing. 
According to Langheinrich (2003), zebrafish embryos elicit comparable responses to 
mammalian embryos when exposed to cardiovascular, anti-cancer, and anti-angiogenic 
drugs. Approximately 70% of zebrafish proteins correspond to human orthologs. 
Langheinrich also found that humans and zebrafish showed a near 100% similarity in 
genes encoding highly conserved functional domains, especially substrate-binding 
regions for drug-binding targets (Langheinrich, 2003).  
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Due to the homology in zebrafish and human drug-binding regions and other 
functional regions, the similar effects of drugs on both zebrafish and mammalian 
embryos, and the transparency of the embryos and larvae allowing for visualization of 
drug effects, the zebrafish is the appropriate model to use when testing the effects of 
CBD and THC on development and behavior. Specifically, CB1 and cnr1 and CB2 and 
cnr2 are similar in function and binding specificity (Langheinrich, 2003). Past studies of 
THC/CBD in zebrafish have shown that early age exposure results in physical deformity 
and behavioral alterations (Carty et al., 2018). 
1.5 Research goals 
 The goal of this study was to further our understanding of the function of CB2. 
This was accomplished by exposing cnr2-/- and fli strains of zebrafish to both THC and 
CBD. After the exposure, we tested larval behavior and scored each fish for physical 
malformations. We ran statistical analyses for physical deformities and behavior, testing 
for significance between treatments and strains. With this information, we tested our 
hypothesis: CB2 is involved in the developmental and behavioral adverse outcomes 
caused by cannabinoid exposure.  
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II. Methods 
2.0 Zebrafish breeding and egg collection 
Tu (cnr1; zf679) and Tu (cnr2; zf680) zebrafish were kindly gifted from Dr. 
Wolfram Goessling’s lab at Harvard University (2012). Adult zebrafish were placed in 
breeding tanks containing water (pH 7.5-8.0, dissolved oxygen 7.2-7.8 mg/L, 
conductivity 730-770 µS, temperature 27-29 oC) from Aquatic Habitats zebrafish flow 
through system (Aquatic Habitats, Apopka, Florida). These breeding tanks are smaller 
boxes that fit into the tanks with holes large enough for eggs and waste to fall through but 
not large enough for the fish to get through. Water in the tank was approximately two 
inches above the bottom of the breeding box. This water level is important to the level of 
reproductive hormone present in the tank to encourage spawning (Graham et al., 2018). 
Zebrafish were spawned in these conditions overnight. The next morning, fertilized eggs 
were collected by tank, placed into petri dishes, and adult zebrafish were returned to their 
tanks. Waste and unfertilized eggs were removed from the petri dishes, and the number 
recorded for fecundity data. System water was removed and replaced with egg water with 
salinity 60 ppm Instant Ocean (Instant Ocean, Cincinnati, Ohio) at pH 7.4-7.7. Dr. 
Zacharias Pandelides kindly provided fli larval deformity and behavioral raw data for this 
study. 
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2.1 Exposure 
The goal was to treat embryos at or near the start of the gastrula period at the 50% 
epiboly stage (5.3 hpf; ~5 hpf). Starting at 5 hpf allows enough time to sort and stage the 
embryos; it also allows for the development of CB1 and CB2 receptors from the four and 
one cell stage, respectively, to the end of the blastula stage (Kimmel et al., 1995; Paria 
and Dey, 2000). The germ ring stage is the beginning of the gastrula period. Embryos are 
all staged to be within 30 minutes of each other to provide accuracy in this developmental 
study, which subsequently ensures experimental reproducibility and the ability to add 
new observations and details (Kimmel et al., 1995). We routinely staged zebrafish within 
an hour of collection to confirm they were fertilized at the same time.  Embryos were 
then assessed an hour before exposure to ensure that the exposure would be starting at the 
correct stage (50% epiboly).  
Exposure groups were a solvent control (dimethyl sulfoxide, (DMSO, 0.05%) 
CBD (0.075, 0.15, 0.3, 0.6, and 1.2 mg/L; 0.25, 0.5, 1, 2, and 4 µM), or (DMSO 0.1%) 
THC (0.625, 1.25, 2.5, 3.0, and 3.75 mg/L; 2.1, 4, 8, 12, and 16 µM). DMSO is a polar 
aprotic solvent that dissolves both polar and nonpolar compounds 
(pubchem.ncbi.nlm.nih.gov). These concentrations of CBD and THC were based on 
previously described experimental data (Carty et al., 2018). Staged embryos were then 
randomly sorted into scintillation vials, n=5 vials per exposure group; 20 embryos per 
vial (thinned to 10 at 24 hpf), containing egg water. This exposure was carried out double 
blind. To start the exposure, at 5 hpf egg water was drained from each scintillation vial 
and 12 mL of treated water (0.6 mL water per embryo) was added. Water was not 
changed throughout the exposure. Vials were then covered with tinfoil and placed into an 
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incubator at 28o C. Exposed embryos were screened every 24 hours to remove debris, 
waste, mortality, and sloughed chorions. At 24 hpf, replicate vials were thinned to the 
desired 10 embryos, which remained in the original dosing vials for the remainder of the 
exposure time. The mentioned exposure protocol followed the approved OECD 
guidelines and recommendations; however, eggs were not exposed at 1 hpf due to timing 
inconvenience and the lack of cnr1 presence at this time point. The NIDA Drug Supply 
Program provided THC and CBD for this study. Following exposure, water samples were 
taken down and cleaned up for later quantification and Gas Chromatography/Mass 
Spectroscopy testing. The GC/MS was out of order for the latter duration of this study. 
2.2 Larval behavior 
At 96 hpf, larvae were transferred from scintillation vials to a 96-well plate to 
assess behavior. Zebrafish larval behavior was then monitored via a ViewPoint Zebrabox 
(ViewPoint, Montreal, Canada) for 30 minutes. In the Zebrabox, larvae underwent 
light:dark:light cycling (0-10 min, 100% light (8000 lux), 10-20 min, 0% light (0 lux), 
20-30 min, 100% light). For each well, larval travel duration at a velocity greater than or 
equal to 5 mm/sec was recorded. This data was then pooled per scintillation vial and 
statistical analyses were performed using a One-way ANOVA test to analyze the dark 
cycle data. Following the Zebrabox behavior assessment, zebrafish were screened for 
touch response, where the larval tail was touched with a pipette tip. This mechanical 
impact either elicited an avoidance swimming response (as to be expected) or did not 
elicit a response at all.  Those that did not elicit a touch response or displayed gross 
physical deformities were removed from behavioral statistical analysis.  
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2.3 Developmental deformity scoring 
Following behavioral assessments, larvae were anesthetized in 300 mg/L tricaine 
methanesulfonate (MS-222) and 600 mg/L sodium bicarbonate. They were immediately 
placed on a microscope slide with a chamber containing 3% methyl cellulose, and photos 
were captured with a MicroFire® camera (Optronics, Goleta, CA) attached to a Zeiss 
Stemi 2000-C Stereo Microscope (Jena, Germany) using Picture Frame™ Application 
2.3 software (Optronics, Goleta, CA). A lateral photo of each larval fish was taken and 
subsequently scored for physical deformities (no swim bladder, yolk sac edema, 
pericardial edema, body axis curvature, micropthalmia, tail) by two independent 
observers blinded to the treatments. Following imaging, the fish were placed in vials of 
RNAlater and stored at -80°C for future analysis.  
2.4 Statistical analysis 
Error was identified as standard error of the mean (SEM) for all data points. LC50 
data was assessed using the USEPA’s TRAP LC50 calculations. Physical deformity data 
comparison between both treatment and strain were assessed using a two-way ANOVA 
followed by a Tukey’s post hoc test. Data for each deformity was also assessed using 
one-way ANOVA followed by Tukey’s post-hoc test (p≤0.05; n=5). 
Throughout a 30-minute period, we continuously collected movement data for 
each larval zebrafish at a velocity of ≥ 5 mm/s for larval zebrafish locomotor behavior 
statistical assessment. Every 2 minutes, the average for activity duration per fish was 
recorded for each dark or light phase for statistical analysis (n=5). The dark behavioral 
data was averaged for each fish, pooled by concentration iteration, and analyzed using a 
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one-way ANOVA followed by a Dunnett’s post-hoc test (p ≤ 0.05). All statistical 
analysis was conducted using Sigma Plot software. 
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III. Results 
3.0 Lethality of THC and CBD  
 After waterborne exposure to either CBD or THC, 96 hpf zebrafish larvae 
exhibited treatment and strain dependent morphological and behavioral toxicities. The 
CBD exposed fli LC50 of 0.72 ± 0.34 mg/L was 28% lower than the CBD exposed cnr2
-/- 
LC50 of 0.92 ± 0.14 mg/L. The THC exposed fli LC50 of 2.97 ± 0.31 mg/L was 13% 
lower than THC exposed cnr2-/- LC50 of 3.35 ± 1 mg/L (Table 2). Comparing fli and 
cnr2-/- when exposed to either CBD or THC, there was no significant difference in 
average survival between fli and cnr2-/- at any concentration (Fig. 2). Therefore, survival 
was not strain dependent, as THC and CBD affect fli and cnr2-/- similarly. However, the 
LC50 estimations in this study were not ideal, as there were few if any mortality data 
points during the linear phase of the LC50 graphs. Therefore, further studies should be 
conducted using concentrations between 0.6 and 1.2 mg/L CBD and 2.5 and 3.75 mg/L 
THC in order to calculate a more accurate LC50.  
The CBD fli LC50 of 0.72 mg/L was 3.125 times lower than the THC fli LC50 of 
2.97 mg/L. The CBD cnr2-/- LC50 of 0.92 mg/L was 2.64 times lower than the THC cnr2
-/- 
LC50 of 3.35 mg/L. fli and cnr2
-/- exhibited higher sensitivity to CBD than THC, as the 
average survival for both fli and cnr2-/- was significantly lower at lower CBD 
concentrations than the average survival at THC concentrations (Fig. 3). 
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Figure 2. Strain dependent LC50 comparison: Fli and cnr2
-/- both show 
increased mortality with increased CBD or THC concentration. The calculated 
LC50 was not significantly different between the two strains (CI overlap).  
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Figure 3. Treatment dependent LC50 comparison: Fli and cnr2
-/- both show higher sensitivity to 
CBD. However, these LC50 estimations were not ideal due to lack of mortality data points along 
the linear phase of the LC50 graphs. Further study should be conducted using concentrations 
between 0.6 and 1.2 mg/L CBD and 2.5 and 3.75 mg/L THC. 
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Control
 
fli 0.6 mg/L  
YSE 
Axis 
Micropthalmia 
PE 
Tail 
fli 0.1% DMSO 
fli 0.6 mg/L CBD 
fli 0.6 mg/L CBD 
fli 3.75 mg/L THC fli 1.25 mg/L THC 
fli 0.6 mg/L CBD 
Table 2. LC50 confidence interval data: Estimated LC50, upper confidence interval (UCL), and 
lower confidence interval (LCL) for CBD cnr2-/-, THC cnr2-/-, CBD fli, and THC fli. 
 CBD THC 
 Guess 95% LCL 95% UCL Guess 95% LCL 95%UCL 
cnr2-/- 0.92 0.78 1.06 3.35 2.35 4.35 
fli 0.72 0.38 1.06 2.9696 2.6596 3.2496 
 
3.1 CBD 
3.1.1 CBD morphology 
 The percent incidence of physical deformities in both fli and cnr2-/- fish were 
significant when comparing both strain and treatment according to two-way ANOVA (p 
≤ 0.05). Namely, yolk sac edema and pericardial edema showed significantly increased 
percent incidence due to strain and treatment (p ≤ 0.05).  Exposure to control, 0.075, 
0.15, 0.3, and 0.6 mg/L CBD did not result in any significant incidence of micropthalmia 
(eyes), axis, or malformed tail in fli and cnr2-/- fish (p > 0.05). The 1.2 mg/L treatment 
was excluded from comparison because mortality was ~100 percent at this treatment for 
both strains. 
 
 
 
 
 
 
 
Figure 4. Physical Deformities in Zebrafish: Imaging fish at 2X magnification, we were able to 
capture photos for more accurate deformity scoring. Each of the fish above exhibit either yolk sac 
edema (YSE), axis, micropthalmia, pericardial edema (PE), or tail malformations. These 
malformations were scored compared to a healthy control fish void of malformations. Minor PE 
is often overlooked; therefore, PE severity is also depicted in the figure. 
 
PE minor 
PE intermediate 
PE major 
fli 0.6 mg/L CBD 
fli 0.6 mg/L CBD 
fli 0.6 mg/L CBD
 
fli 0.6 mg/L CBD  
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 Yolk sac edema (YSE) incidence was statistically significant across treatment and 
strain (Fig. 4). The fli exposed to 0.6 mg/L CBD had 62.5 ± 20.1 % YE which was 
significantly higher than all treatments except 0.6 mg/L cnr2-/-.  There was no significant 
difference between any other treatments or the strains.  
 In fli larvae, pericardial edema (PE) incidence was significantly increased across 
both treatment and strain (Fig. 5). In fli larvae at 0.6 mg/L, the incidence of PE was  
30.0 ± 3.7%, which was significantly greater than PE incidence at all other fli exposure 
treatments. There was a significant 27.8% percent increased incidence at 0.6 mg/L CBD 
in fli compared to the cnr2-/- fish. There was less than a 5% incidence of PE at 0.6 mg/L 
and no incidence of PE for the cnr2-/- fish at control, 0.075, 0.15, and 0.3 mg/L.  
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Figure 5. Percent incidence of YSE between fli and cnr2-/- Using a one-way ANOVA, we 
assessed the average percent incidence of YSE ± the standard error for each CBD treatment 
(n=5). Percent incidence of YSE between fli and cnr2-/- larvae: fli 0.6 mg/L exposed larvae 
showed significantly greater YSE percent incidence than other treatment groups. 
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Figure 6. Percent incidence of PE between fli and cnr2-/-: Using a one-way ANOVA, we 
assessed the average percent incidence of PE ± the standard error for each CBD treatment 
(n=5). Percent incidence of PE between fli and cnr2-/- larvae: fli 0.6 mg/L exposed larvae 
showed significantly greater PE percent incidence than other treatment groups. 
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Table 3. Summary table of CBD malformations: Mean percent incidence and standard error 
(mean ± SE) of each malformation found in both fli and cnr2-/- strain fish. An asterisk indicates 
significant increase percent incidence of toxicity. 
 
 CBD Malformations (%) 
Treatment 
(mg/L)  
Strain YSE PE Axis Eyes Tail 
0.05% DMSO cnr2-/-  4.0 ± 4.0 2.0 ± 2.0 6.0 ± 2.4 4.0 ± 4.0 2.0 ± 2.0 
0.075 cnr2-/- 5.0 ± 2.0 0.0 ± 0.0 4.2 ± 2.6 0.0 ± 0.0 0.0 ± 0.0 
0.15 cnr2-/- 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
0.3 cnr2-/- 3.5 ± 2.9 0.0 ± 0.0 8.4 ± 4.3 0.0 ± 0.0 0.0 ± 0.0 
0.6 cnr2-/- 26.9 ± 2.8 2.8 ± 2.8 23.6 ± 9.7 5.6 ± 5.6 0.0 ± 0.0 
1.2 cnr2-/- n/a n/a n/a n/a n/a 
0.05% DMSO fli 24.0 ± 7.4 0.0 ± 0.0 2.0 ± 2.0 0.0 ± 0.0 2.2 ± 2.2 
0.075 fli 8.0 ± 3.7 2.0 ± 2.0 2.0 ± 2.0 0.0 ± 0.0 0.0 ± 0.0 
0.15 fli 3.3 ± 2.6 0.0 ± 0.0 3.3 ± 2.6 0.0 ± 0.0 0.0 ± 0.0 
0.3 fli 19.2 ± 4.1 2.0 ± 2.0 4.2 ± 2.6 0.0 ± 0.0 4.2 ± 2.6 
0.6 fli 62.5 ± 20.1* 30.0 ± 3.7* 12.5 ± 6.7 5.0 ± 4.5 0.0 ± 0.0 
1.2 fli n/a n/a n/a n/a n/a 
 
3.1.2 Behavior of cnr2-/- exposed to CBD 
Zebrafish larval behavior was assessed via speed and duration of movement 
during light and dark conditions. Wildtype zebrafish larvae tend to exhibit 
hypolocomotor activity during light periods and hyperlocomotor activity during dark 
periods (Kirla et al., 2016). CBD exposed cnr2-/- light/dark larval behavioral assessment 
is in accordance with what was expected (Fig. 6). Therefore, movement in the dark at a 
velocity ≥5 mm/s- was the focus in this study. 
cnr2-/- larvae exposed to 0.075 mg/L CBD exhibited a significant 79.72% increase 
in movement duration (seconds of duration ≥5 mm/s) during dark periods compared to 
control larvae. CBD 0.15, 0.3, and 0.6 mg/L treatments did not show significant 
differences in duration of movement during dark periods from control.  
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Figure 7. CBD light/dark behavioral patterns in cnr2-/-. In the graph above, each dot represents the 
average activity over a two minute time interval ± the standard error for each treatment (n=300). 
cnr2-/- exhibited hypolocomotor activity during periods of light exposure, as seen in the first and 
last ten minute intervals. The hyperlocomotor activity period occurs during the dark period, as 
seen by the gradual increase, spike, and decrease in activity from 10-20 minutes. To decrease 
standard error, the sample size should be increased and each fish should pass the swim-up test to 
be included in analysis. 
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Figure 8. CBD cnr2-/- average dark period locomotion: Using a one-way ANOVA, the average 
duration of activity (velocity ≥ 5 mm/s) was assessed for each fish (n=300) during dark exposure 
in larval zebrafish. CBD exposed larvae exhibited non-monotonic dose-dependent behavioral 
patterns. Compared to control, the 0.075 mg/L treatment group showed the largest activity 
duration, 0.15, 0.3, and 0.6 mg/L exposed larvae had activities that were not different than control 
fish. 
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3.2 THC 
3.2.1 THC morphology 
 The percent incidence of physical deformity in both fli and cnr2-/- fish were 
treatment dependent according to two-way ANOVA statistical tests. Yolk sac edema, 
micropthalmia, pericardial edema, axis curvature, and malformed tail were not 
significantly percent different between strain or treatment at control, 0.65, 1.25, and 2.5 
mg/L treatments, and 3.00 mg/L and 3.75 mg/L were excluded from comparison due to 
either ~100 percent mortality or lack of replication in fli.  
 Previous studies showed that embryos exposed to THC suffered from yolk sac 
edema. Yolk sac edema was not statistically different across strain (Fig. 7). fli exposed to 
2.5 mg/L exhibited a percent incidence of 56.7 ± 14.8%, which was significantly greater 
than all other treatments except cnr2-/-1.25 and 2.5 mg/L and control larvae. At 1.25 
mg/L, cnr2-/- had statistically more yolk sac edema than fli.  
 
 
 
 
 
 
 
 
 
 2-/- 
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Figure 9. Comparison of YSE percent incidence between fli and cnr2-/-: Using a one-way 
ANOVA, the average percent incidence of YSE ± the standard error for each THC treatment 
(n=3) was assessed. Percent incidence of YSE was significantly greater in fli and cnr2-/- in 2.5 
mg/L exposed larvae, 1.25 mg/L exposed larvae, and control larvae. A high percentage of control 
larvae showed yolk sac edema. Further study with a higher sample group is needed to explain this 
phenomenon.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31 
 
  
Table 4. Summary table of THC malformations: Mean percent incidence and standard error 
(mean ± SE) of each malformation found in both fli and cnr2-/- strain fish. An asterisk indicates 
significant increase percent incidence of toxicity. 
 THC Malformations (%) 
Treatment 
(mg/L) 
Strain YSE PE Axis Eyes Tail 
0.1% 
DMSO 
cnr2-/- 6.7 ± 11.56 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 6.67 ± 11.56 
0.65 cnr2-/- 0.0 ± 0.0 0.0 ± 0.0 3.3 ± 5.8 0.0 ± 0.0 3.3 ± 5.8 
1.25 cnr2-/- 31.25 ± 8.8  12.5 ± 0.0 25 ± 17.7  0.0 ± 0.0 12.5 ± 17.7 
2.5 cnr2-/- 55.5 ± 9.6* 53.8 ± 29.6 55.8 ± 38.4 0.0 ± 0.0 12.5 ± 17.7 
0.1% 
DMSO 
fli 19.0 ± 9.8  12.9 ± 1.1 53.3 ± 9.9 0.0 ± 0.0 4.8 ± 3.7 
0.65 fli 7.0 ± 2.7 0.0 ± 0.0 10.7 ± 5.0 0.0 ± 0.0 0.0 ± 0.0 
1.25 fli 8.7 ± 4.1 19.3 ± 9.1 17.1 ± 4.7 4.2 ± 2.6 6.2 ± 4.1 
2.5 fli 56.7 ± 14.8 46.7 ± 15.5 31.3 ± 14.2 0.0 ± 0.0 9.3 ± 6.1 
 
3.2.2 Behavior of cnr2-/- exposed to THC 
THC cnr2-/- light/dark larval behavioral assessment was only in accordance with 
wildtype zebrafish behavior at the lowest sub-lethal THC treatment (Fig. 10) (Kirla et al., 
2016). 
Duration of movement at velocity ≥5 mm/s during the dark period of behavioral 
analysis was also calculated after THC exposure (Fig. 11). Larvae exposed to 0.65 mg/L 
THC showed a significant 83.93% increase in movement duration (seconds of duration 
≥5 mm/s) during dark periods compared to control. THC 1.25, 2.5, and 3.75 mg/L 
treatments did not show significant differences in duration of movement during dark 
periods from control.  
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Figure 10. THC light/dark behavioral patterns in cnr2-/-. In the graph above, each dot represents 
the average activity over a two minute time interval ± the standard error for each treatment 
(n=180). cnr2-/- exhibit a reversal of the typical behavioral pattern: hyperlocomotor activity 
during light periods and hyolocomotor activity during the dark period. The only concentration 
that follows the typical behavioral pattern is the lowest THC concentration. Our control only 
shows a slight and gradual increase in activity during the dark period and a spike in activity 
during the last light period. To decrease standard error, the sample size should be increased and 
each fish should pass the swim-up test to be included in analysis. 
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Figure 11. THC cnr2-/- average dark period locomotion: Using a one-way ANOVA, the average 
duration of activity (velocity ≥ 5 mm/s) during dark exposure in larval zebrafish dose-dependent 
(n=180) was assessed. THC exposed specimen exhibit non-monotonic behavioral patterns. 
Compared to control, the 0.65 mg/L treatment group showed the largest activity duration, and 
1.25, 2.5, and 3.75 mg/L larvae were not statistically different than control. 
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IV. Discussion 
4.0 Lethality of THC and CBD 
 Our tested LC50 values for fli and cnr2
-/- CBD and THC exposures confirm 
previous LC50 data. THC LC50 values of cnr2
-/- 3.35 mg/L and fli 2.97 mg/L confirmed 
previous THC LC50 data (3.37 mg/L, 3.65 mg/L) (Akhtar et al., 2013; Carty et al., 2018). 
CBD LC50 values of cnr2
-/- 0.92 mg/L and fli 0.72 mg/L confirm previous CBD LC50 
values (0.53 mg/L) (Carty et al., 2018). We expected CBD LC50 values to be lower than 
than THC LC50 values, it was previously published that wildtype zebrafish exposure to 
THC and CBD produced a CBD LC50 ~7 times lower than THC LC50 (Carty et al., 2018). 
As Carty (2018) explained, lower CBD LC50 values cannot be attributed to increased 
potency but to more efficient bioconcentration of CBD in larvae tissues. The slight 
differences between our THC and CBD LC50 values and Carty (2018) LC50 values can be 
attributed to the time of exposure. In Carty (2018), embryos were exposed at the 
beginning of the blastula stage, and here embryos were not exposeduntil the end of the 
blastula stage at 50% epiboly. According to previous studies, earlier life stage exposure 
elicits increased frequency of dysmorphologies, leading to higher rates of mortality 
(Bloch et al., 1986; Harbison et al., 1977; Outcomes et al., 2003). 
4.1 CBD and THC morphology  
 CBD and THC exposure produced similar concentration-dependent toxicities, 
namely yolk sac edema and pericardial edema. It was expected that that CBD and THC 
would produce similar malformational outcomes in fli zebrafish development because of 
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previous work in our laboratory (Carty et al., 2018). However, Carty (2018) noted several 
morphologic outcomes in compound exposed fli larvae that we did not observe with 
statistical significance: missing pectoral fins, swim bladder distention, axis, 
micropthalmia, snout, jaw, and tail deformity. Like out study, Carty (2018) also noted 
significant percent incidence in yolk sac edema and pericardial edema but at lower 
concentrations than those at which we recorded. There are two reasons that can account 
for these differences. First, Carty (2018) exposed embryos at an earlier life stage, 
increasing the frequency of physical malformations (Bloch et al., 1986; Harbison et al., 
1977). Second, our experiment was double-blind, whereas Carty’s (2018) was not. A 
double-blind experiment can produce more accurate data, because a double-blind 
experiment reduces hypothesis bias in scoring malformations. Because of these 
differences, we only saw significant increase in yolk sac edema and pericardial edema at 
fli CBD 0.6 mg/L and yolk sac edema at fli and cnr2-/- THC 2.5 mg/L. 
4.1.1 CB2 and cardiac function 
 CB1 and CB2 receptors have been located in the hearts of several mammalian 
species: rat (Bouchard et al., 2003; Lépicier et al., 2003), mouse (Duerr et al., 2014), 
guinea pig (Currie et al., 2008), and human (Weis et al., 2010). These receptors have also 
been located on the hearts of zebrafish (Krug et al., 2015). These receptors are involved 
in acute cardiovascular conditions, namely septic, hemorrhagic, and cardiogenic shock, 
along with chronic diseases, such as heart failure, cardiomyopathy, and coronary heart 
disease (Kaschina, 2016). By acting on these receptors, cannabinoids stimulate cardiac 
function (Matsuda et al., 1990; Munro et al., 1993). In the cardiac system, CB2 acts as an 
agent of cardiovascular protection against acute cardiovascular conditions, contributing 
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anti-inflammatory, anti-atherogenic, and anti-oxidative abilities (Mukhopadhyay et al., 
2010; Steffens et al., 2005). Several studies have reported marked upregulation of CB2 
following cardiac injury, such as myocardial infarction in rats (Wagner et al., 2001) and 
ischemia/reperfusion in mice (Duerr et al., 2014). CBD has a low affinity for CB2, but at 
increasing concentrations, CB2 becomes saturated with CBD (Kendall and Alexander, 
2017). Our data shows that sub-lethal dose CBD exposure to fli strain zebrafish at early 
life stages results in a dose dependent significant increase in percent incidence of 
pericardial edema. In cnr2-/- fish exposed to the same concentrations of CBD, this adverse 
outcome was not observed. Therefore, we concluded that CBD binding to CB2 could be 
contributing to the cardiac toxicity seen in wildtype fish. CB2 receptor may interact in a 
way to either allosterically alter the shape of the primary binding site, competitively 
inhibit binding of other substrates, or act on the receptor in another form. Exposure to 
THC did not have these effects most likely due to the fact that THC acts on CB2 in a 
different fashion.  
4.1.2 CB2 and hematopoiesis 
 The first site of hematopoiesis in zebrafish occurs in the intermediate cell mass, 
which later develops in to the yolk sac and is comparable to the mouse amniotic sac 
(Kulkeaw and Sugiyama, 2012). CB2 is primarily located on cells of hematopoietic origin 
across species, and therefore is most likely found in the zebrafish yolk sac (Basu and 
Dittel, 2011). When endogenous cannabinoids bind to CB1 and CB2 receptors in 
hematopoietic cells, these cannabinoids act as growth stimulators for hematopoietic cells 
and inhibitors of lymphocyte proliferation and tumor necrosis factorK production 
(Derocq et al., 1998). Phytocannabinoid binding to CB1 and CB2 should produce similar 
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effects. In our study, fli larvae suffered from yolk sac edema following exposure to CBD. 
Both fli and cnr2-/- suffered from yolk sac edema following THC exposure. CBD binding 
to CB2, may have caused uncontrolled growth of hematopoietic cells within the yolk sac. 
This growth and proliferation resulted in yolk sac edema. In cnr2-/- larvae, only those 
exposed to the highest sub-lethal concentrations of THC yielded percent incidence 
similar to fli larvae at those concentrations. cnr2-/- at 1.25 mg/L THC showed 
significantly higher percent incidence of yolk sac edema than fli. Control larvae also 
showed a significant increase in yolk sac edema; further study with a higher sample size 
should be conducted to investigate this finding. These results may be due to the fact that 
THC interacts with CB2 differently than CBD.   
4.2 Light/dark behavioral assessment 
 According to Kirla (2016), zebrafish tend to elicit hypolocomotor activity under 
light conditions and hyperlocomotor activity under dark conditions. Our assessment of 
CBD light/dark behavior corresponds to this finding. During the first and last ten minutes 
of larval behavioral assessment, little to no movement greater than or equal to 5 mm/s 
was recorded; these time periods correspond to the light periods of testing. There was a 
dramatic spike in activity during the intermediate ten minute assessment interval, which 
corresponded to the dark period. Our assessment of THC light/dark behavior did not 
follow this model. In all treatments aside from 0.65 mg/L, there was no distinction in 
activity levels between the light and dark phases. This trend indicates that higher THC 
concentrations induce stress and anxiogenic-like behavior (Ellis et al., 2012). It also 
suggests that a neurotoxic event induced by higher THC concentrations may be inducing 
molecular signaling and altering behavior (Kim et al., 2013). Carty (2018) observed 
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similar activity at higher exposure concentrations of both CBD and THC. We did not 
observe these effects in higher concentrations of CBD, and this finding can be attributed 
to later life stage exposure.  
4.2.1 Dark phase behavioral assessment 
 According to several studies, both THC and CBD act as stimulants at low 
concentrations (Achenbach et al., 2018; Akhtar et al., 2013). In Achenbach (2018), 
average larval distance traveled was significantly higher at lower concentrations as 
opposed to higher concentrations. Our data confirms these previous studies, as we found 
that cnr2-/- larvae exposed to 0.075 mg/L CBD had a significantly greater duration of 
activity during the dark period than larvae exposed to any other treatment. In Akhtar 
(2013) and Carty (2018), larval behavior of THC exposed larvae were greater at lower 
concentrations than higher concentrations. 
We found that cnr2-/- larvae exposed to 0.65 mg/L THC had a significantly 
greater duration of activity during the dark period than larvae exposed to any other 
treatment. THC and CBD stimulate neuronal signaling pathways at low concentrations 
and have either a normalizing or depressing effect at higher concentrations.  
4.3 Conclusion 
 Our investigation into the effects of CBD and THC on specific receptors in the 
endocannabinoid system is highly relevant in today’s world of ever expanding cannabis 
research. Toxicology, epilepsy, and cancer research fields, to name a few, are beginning 
to utilize cannabinoid enriched drugs in treatment. Additionally, pregnant women are 
self-medicating with CBD. Therefore, it is important to know exactly how THC and CBD 
interact with our bodies and may interfere with early development. In order to understand 
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these potential adverse outcomes, it is important to understand the molecular mechanisms 
by which these compounds primarily interact, including the endocannabinoid system and 
its receptors, CB1 and CB2. 
 The endocannabinoid system is still very much a mystery, and even less research 
has been conducted to understand the role of CB2. Through this study, I believe that we 
have added a piece to the endocannabinoid puzzle by unveiling a few of CB2’s functions 
in the presence of CBD and THC. In regards to organogenesis, CBD negatively affected 
both cardiac and hematopoietic development via interactions with CB2. THC does not 
appear to directly interact with CB2 to affect hematopoietic development. From our 
studies, CB2 does not appear to play a major role in larval behavior, as behavioral 
patterns for cnr2-/- exposed to either THC or CBD followed predicted, non-monotonic 
behavioral patterns of wildtype fish exposed the same compounds. By understanding the 
role of CB2, we can further understand the development of toxicities that THC and CBD 
can cause and minimize the adverse outcomes mediated by developmental cannabinoid 
exposure in the future. 
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